MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehy811

Медицинская библиотека · European heart journal · 2019

β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.

Sorbets Emmanuel, Steg Philippe Gabriel, Young Robin, Danchin Nicolas, Greenlaw Nicola, Ford Ian, Tendera Michal, Ferrari Roberto, Merkely Bela, Parkhomenko Alexander, Reid Christopher, Tardif Jean-Claude, Fox Kim M, CLARIFY investigators

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: The effect of first-line antianginal agents, β-blockers, and calcium antagonists on clinical outcomes in stable coronary artery disease (CAD) remains uncertain.

METHODS AND

RESULTS

We analysed the use of β-blockers or calcium antagonists (baseline and annually) and outcomes in 22 006 stable CAD patients (enrolled 2009-2010) followed annually to 5 years, in the CLARIFY registry (45 countries). Primary outcome was all-cause death. Secondary outcomes were cardiovascular death and the composite of cardiovascular death/non-fatal myocardial infarction (MI). After multivariable adjustment, baseline β-blocker use was not associated with lower all-cause death [1345 (7.8%) in users vs. 407 (8.4%) in non-users; hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.84-1.06; P = 0.30]; cardiovascular death [861 (5.0%) vs. 262 (5.4%); HR 0.91, 95% CI 0.79-1.05; P = 0.20]; or cardiovascular death/non-fatal MI [1272 (7.4%) vs. 340 (7.0%); HR 1.03, 95% CI 0.91-1.16; P = 0.66]. Sensitivity analyses according to β-blocker use over time and to prescribed dose produced similar results. Among prior MI patients, for those enrolled in the year following MI, baseline β-blocker use was associated with lower all-cause death [205 (7.0%) vs. 59 (10.3%); HR 0.68, 95% CI 0.50-0.91; P = 0.01]; cardiovascular death [132 (4.5%) vs. 49 (8.5%); HR 0.52, 95% CI 0.37-0.73; P = 0.0001]; and cardiovascular death/non-fatal MI [212 (7.2%) vs. 59 (10.3%); HR 0.69, 95% CI 0.52-0.93; P = 0.01]. Calcium antagonists were not associated with any difference in mortality.

CONCLUSION

In this contemporary cohort of stable CAD, β-blocker use was associated with lower 5-year mortality only in patients enrolled in the year following MI. Use of calcium antagonists was not associated with superior mortality, regardless of history of MI.

Для цитирования: Sorbets Emmanuel, Steg Philippe Gabriel, Young Robin, Danchin Nicolas, Greenlaw Nicola, Ford Ian, Tendera Michal, Ferrari Roberto, Merkely Bela, Parkhomenko Alexander, Reid Christopher, Tardif Jean-Claude, Fox Kim M, CLARIFY investigators. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study.. European heart journal. 2019. DOI: 10.1093/eurheartj/ehy811.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.